JPWO2020193995A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020193995A5
JPWO2020193995A5 JP2021557824A JP2021557824A JPWO2020193995A5 JP WO2020193995 A5 JPWO2020193995 A5 JP WO2020193995A5 JP 2021557824 A JP2021557824 A JP 2021557824A JP 2021557824 A JP2021557824 A JP 2021557824A JP WO2020193995 A5 JPWO2020193995 A5 JP WO2020193995A5
Authority
JP
Japan
Prior art keywords
recovery
cya
test
sonication
methanol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021557824A
Other languages
Japanese (ja)
Other versions
JP7519107B2 (en
JP2022528853A (en
Publication date
Priority claimed from GBGB1904336.3A external-priority patent/GB201904336D0/en
Application filed filed Critical
Publication of JP2022528853A publication Critical patent/JP2022528853A/en
Publication of JPWO2020193995A5 publication Critical patent/JPWO2020193995A5/ja
Application granted granted Critical
Publication of JP7519107B2 publication Critical patent/JP7519107B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Description

ケイ素ナノ粒子からのＣｙＡの回収を試験するため、１時間にわたってメタノール及び音波処理を用いて表５の製剤を消化するための方法を開発した。各凍結乾燥製剤をメタノールに懸濁して、０．０５ｍｇ／ｍｌの理論上のＣｙＡ濃度を得た。音波処理を３０分間行ってから、ＨＰＬＣによって分析した。結果を表６に示す。

Figure 2020193995000001
To test the recovery of CyA from silicon nanoparticles, a method was developed to digest the formulations in Table 5 using methanol and sonication for 1 hour. Each lyophilized formulation was suspended in methanol to obtain a theoretical CyA concentration of 0.05 mg/ml. Sonication was performed for 30 minutes before analysis by HPLC. The results are shown in Table 6.
Figure 2020193995000001

ＡＰＩの回収の試験に用いられるプロトコルは、上述のＣｙＡの回収の試験に用いられるものに対応する。ＡＰＩ回収の結果を表８に示す。

Figure 2020193995000002
The protocol used to test API recovery corresponds to that used to test CyA recovery described above. The API recovery results are shown in Table 8.
Figure 2020193995000002

JP2021557824A 2019-03-28 2020-03-30 Delivery systems including silicon-containing materials - Patents.com Active JP7519107B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1904336.3 2019-03-28
GBGB1904336.3A GB201904336D0 (en) 2019-03-28 2019-03-28 A delivery system
PCT/GB2020/050849 WO2020193995A1 (en) 2019-03-28 2020-03-30 A delivery system comprising silicon-containing material

Publications (3)

Publication Number Publication Date
JP2022528853A JP2022528853A (en) 2022-06-16
JPWO2020193995A5 true JPWO2020193995A5 (en) 2024-05-15
JP7519107B2 JP7519107B2 (en) 2024-07-19

Family

ID=66442907

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021557824A Active JP7519107B2 (en) 2019-03-28 2020-03-30 Delivery systems including silicon-containing materials - Patents.com

Country Status (8)

Country Link
US (1) US20220183989A1 (en)
EP (1) EP3946257A1 (en)
JP (1) JP7519107B2 (en)
CN (1) CN113645957A (en)
AU (1) AU2020249806A1 (en)
CA (1) CA3144011A1 (en)
GB (1) GB201904336D0 (en)
WO (1) WO2020193995A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202110645D0 (en) * 2021-07-23 2021-09-08 Sisaf Ltd Protection of biological molecules from degradation
GB202210794D0 (en) 2022-07-22 2022-09-07 Sisaf Ltd Lipid formulations
GB202300911D0 (en) * 2023-01-20 2023-03-08 Sisaf Ltd Therapeutic compositions and methods

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL9400189A (en) 1994-02-07 1995-09-01 Bio Pharma Sciences Bv Stabilized orthosilicic acid-containing preparation, a method for its preparation and a biological preparation.
FR2799758B1 (en) 1999-10-15 2002-05-17 Exsymol Sa COMPLEX BASED ON BIOLOGICALLY ASSIMILABLE ORTHOSILICIC ACID, IN SOLID, STABLE AND CONCENTRATED FORM, AND PREPARATION METHOD
EP1391426A1 (en) 2002-08-12 2004-02-25 Bio Minerals N.V. Method for the preparation of a silicic acid comprising extrudate, said extrudate, its use and a pharmaceutical composition comprising the said extrudate
US20100172993A1 (en) * 2006-08-11 2010-07-08 Amarjit Singh Particles for delivery of active ingredients, process of making and compositions thereof
IT1394656B1 (en) 2009-07-03 2012-07-05 Brev Angela Srl PROCESS FOR THE PRODUCTION AND ASSEMBLY OF A SYRINGE FOR MEDICAL OPERATIONS
GB0913255D0 (en) 2009-07-30 2009-09-02 Sisaf Ltd Topical composition
EP2605755B1 (en) * 2010-08-16 2019-07-31 Australian Nuclear Science & Technology Organisation Particulate substances comprising ceramic particles for delivery of biomolecules
EP2640350B1 (en) 2010-11-18 2018-09-26 Steven Yoelin Compositions and methods for hair growth
AU2015267200B2 (en) * 2014-05-29 2019-01-03 Cornell University Nanoparticle drug conjugates
CN104127886A (en) 2014-07-16 2014-11-05 上海理工大学 CpG nucleic acid drug conveying system and making method thereof
CN107920964B (en) * 2015-07-09 2022-02-25 加利福尼亚大学董事会 Fusogenic liposome-coated porous silicon nanoparticles
US20180344641A1 (en) * 2015-09-04 2018-12-06 C. Jeffrey Brinker Mesoporous silica nanoparticles and supported lipid bi-layer nanoparticles for biomedical applications
CN114949250A (en) 2016-04-14 2022-08-30 斯宾纳克生物科学公司 Compositions for delivery of therapeutic agents, pharmaceutical compositions, methods of preparation and uses

Similar Documents

Publication Publication Date Title
FI3246044T4 (en) Stable formulations of neisseria meningitidis rlp2086 antigens
BRPI0411505A (en) use of a compound, method for modulating an individual's immune response, pharmaceutical composition, vaccine, complex, and kit for capturing a biologically active molecule
EA200601761A1 (en) COMPOSITIONS AS ADJUVANTS FOR STRENGTHENING IMMUNE RESPONSES TO VACCINES AND METHODS OF THEIR USE
JP2017507995A5 (en)
RU2017129340A (en) COMPOSITIONS OF NEISSERIA MENINGITIDIS AND METHODS FOR PRODUCING THEM
JPWO2020193995A5 (en)
Zhu et al. Simultaneous determination of two iridoid glycosides, two anthraquinones and four flavonoid glycosides of Zhi-Zi-Da-Huang decoction in rat plasma by UFLC-MS/MS: application to a comparative pharmacokinetic study in normal and cholestatic liver injury rats
CN1149834A (en) Cyclosporin containing composition and process for preparation
JP2023089120A (en) Novel pharmaceutical compositions for basic or neutral, low molecular weight compounds
Dhanwate et al. Development and validation of analytical method for the estimation of lamivudine and dolutegravir sodium in dosage form
IT9021263A1 (en) ORAL PHARMACEUTICAL COMPOSITIONS BASED ON MELATONIN
Vesterbacka et al. Effects of co-trimoxazole on microbial translocation in HIV-1-infected patients initiating antiretroviral therapy
AR122060A1 (en) ANTI-IL-33 ANTIBODY FORMULATIONS AND METHODS OF USE THEREOF
Decloedt et al. The pharmacokinetics of lopinavir/ritonavir when given with isoniazid in South African HIV-infected individuals
Jaw-Tsai et al. Comparison of pharmacokinetics and bioavailability of bedaquiline fumarate, benzoate and maleate in dogs
Zheng et al. Investigation of a potential pharmacokinetic interaction between perindopril arginine and amlodipine when administered as a single perindopril/amlodipine fixed-dose combination tablet in healthy Chinese male volunteers
CN114404382B (en) Nidamib ethane sulfonate soft capsule and preparation method thereof
SI1784161T1 (en) Controlled-release formulation comprising tamsulosin hydrochloride
Usui et al. A case of pulmonary alveolar microlithiasis
FU et al. Effect of protease activated receptor 2 on colonic transport in chronic stress mice
Ashokraj et al. Plasma pooling: utility in expediting bioequivalence assessment of rifampicin-containing fixed-dose combinations
Youle et al. Clinical, immunological, and virological effects of sodium fusidate in patients with AIDS or AIDS-related complex (ARC): an open study
Yuan et al. Effect of Wuziyanzong pill on metabolism of dapoxetine in vivo and in vitro
Yan et al. Comparison of caries and sealants between Shanghai native and migrant 12-year-old students from 2013 to 2015# br
Leal et al. Examination of In Vitro Release Kinetics of Cidofovir from Different Topical Dosage Forms by using Ultraviolet Spectrophotometry